Expertise in
18
conditions

Dr. Dukagjin Blakaj

Radiation Oncology
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 
Expertise in
18
conditions
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 

Overview

Dukagjin Blakaj is a Radiation Oncologist in Columbus, Ohio. Dr. Blakaj is highly rated in 18 conditions, according to our data. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Laminectomy, and Gamma Knife Radiosurgery.

His clinical research consists of co-authoring 134 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Radiology in OH

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Ohio State University Hospital-Pavilion
300 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
A Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
A Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

134 Total Publications

Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer.
Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer.
Journal: JAMA otolaryngology-- head & neck surgery
Published: April 02, 2026
Similar Doctors
Expertise in
36
conditions
Dr. Joshua Palmer
Radiation Oncology
Expertise in
36
conditions
Dr. Joshua Palmer
Radiation Oncology

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.7 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Palmer is a Radiation Oncologist in Columbus, Ohio. Dr. Palmer is highly rated in 36 conditions, according to our data. His top areas of expertise are Meningioma, Astrocytoma, Brain Tumor, Pancreaticoduodenectomy, and Spinal Fusion.

Expertise in
7
conditions
Dr. Arnab Chakravarti
Radiation Oncology
Expertise in
7
conditions
Dr. Arnab Chakravarti
Radiation Oncology

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.7 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances

Arnab Chakravarti is a Radiation Oncologist in Columbus, Ohio. Dr. Chakravarti is highly rated in 7 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

Expertise in
11
conditions
Dr. Allison Quick
Radiation Oncology
Expertise in
11
conditions
Dr. Allison Quick
Radiation Oncology

The Arthur G. James Cancer Hospital And Richard J. Solove Research Institute

460 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances

Allison Quick is a Radiation Oncologist in Columbus, Ohio. Dr. Quick is highly rated in 11 conditions, according to our data. Her top areas of expertise are Vaginal Cancer, Cervical Cancer, Endometrial Cancer, and Vulvar Cancer.

Frequently Asked Questions about Dr. Dukagjin Blakaj

How do I make an appointment with Dr. Dukagjin Blakaj?

You can book an appointment with Dr. Dukagjin Blakaj by calling their office at 614-366-7744. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dukagjin Blakaj a top-rated expert for Laryngeal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dukagjin Blakaj is classified as an Distinguished expert for Laryngeal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dukagjin Blakaj specialize in?

While Dr. Dukagjin Blakaj is a Radiation Oncology, they have specific expertise in Laryngeal Cancer, Throat Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Dukagjin Blakaj participate in research or clinical trials?

Yes. Dr. Dukagjin Blakaj has published 134 articles and abstracts on conditions like Laryngeal Cancer. You can view a list of Dr. Dukagjin Blakaj's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dukagjin Blakaj accept my insurance?

Dr. Dukagjin Blakaj accepts most major insurance plans, including CareSource and Humana. We recommend calling the office directly at 614-366-7744 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blakaj's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile